– Collaboration leverages Anima’s mRNA Lightning technology platform and AbbVie’s extensive expertise in Oncology and Immunology
– Anima will receive an upfront payment of $42 million with potential for further milestones and royalties

NORTH CHICAGO, Ill. and BERNARDSVILLE, N. J. , Jan. 10, 2023 /PRNewswire/ — AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will certainly use its mRNA Super platform to find out novel mRNA biology modulators against the collaboration focuses on providing AbbVie exclusive rights to license and further develop and commercialize the programs.

“This collaboration will give AbbVie access to Anima’s leading technology platform plus deep experience in mRNA biology and will help further strengthen AbbVie’s world class capabilities in discovering plus developing drugs to make a difference in patient’s lives, ” said Jonathon Sedgwick , Ph. D., vice president and global head of discovery research, AbbVie. “Modulating mRNA biology with small molecules is a new approach and has the potential to address ‘undruggable’ targets along with implications across multiple therapy areas. ”

“Anima’s differentiated approach in the field of small molecule mRNA medicines combines phenotypic screening with AI-driven elucidation of the particular mechanisms associated with action. The power of our mRNA Lightning platform is validated by our multiple partnerships and a growing internal pipeline, inch said Yochi Slonim , co-founder and chief executive officer, Anima. “We are excited in order to partner with AbbVie, a recognized worldwide leader within Oncology plus Immunology,   and are looking forward to start working along with their excellent scientific team in a close cooperation. inch

Under the terms of the agreement, Anima will receive an upfront payment of  $42 million  and may be eligible in order to receive up to  $540 million  in option fees and research and development milestones in the aggregate across the three goals, with potential for further commercial milestones as well as tiered royalties on net sales. AbbVie has an option to expand the collaboration with upward to three additional targets under the same terms as the initial cooperation, which may increase the potential value of the collaboration.  

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges associated with tomorrow. We strive to have a remarkable impact on people’s lives throughout several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and gastroenterology, in addition to products and services across the Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at http://www.abbvie.com . Follow @abbvie on Twitter , Facebook , Instagram , YouTube   and LinkedIn .

About Anima Biotech

Anima Biotech will be advancing mRNA Lightning, the novel system for the particular discovery of small chemical mRNA medications and their mechanisms associated with action. Our differentiated strategy combines high scale phenotypic screening that automates millions of experiments in live mRNA the field of biology with MOAi technology using AI in order to elucidate the mechanism of action associated with active molecules. This unparalleled level of automation associated with phenotypic screening of mRNA modulators together with our AI driven MOA elucidation enabled all of us to create a broad pipeline across 18 different discovery programs inside various therapeutic areas. With our deep knowledge in mRNA biology, we were able to advance them at unprecedented speed plus success rate. Anima wholly owned pipeline programs are in Fibrosis (Collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), Oncology (c-Myc mRNA the field of biology modulators and mutation agnostic mKras mRNA biology modulators), and Neuroscience (Tau — Alzheimer’s disease and Pain – Nav1. 7 mRNA biology modulators).

In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly, Takeda Pharmaceuticals and AbbVie. Our science was further validated with seven patents, 15 peer reviewed publications and 17 scientific collaborations. To learn more about us, visit https://www.animabiotech.com plus follow @AnimaBiotech on LinkedIn and Tweets .

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the particular Private Securities Litigation Reform Act of 1995. The words “believe, inches “expect, ” “anticipate, inch “project” and similar expressions, among others, generally identify forward-looking claims. AbbVie cautions that these forward-looking statements are usually subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such dangers and questions include, but are not limited to, failure to realize the expected benefits from AbbVie’s acquisition of Allergan plc (“Allergan”), failure in order to promptly plus effectively integrate Allergan’s businesses, competition through other items, challenges to intellectual property, difficulties inherent in the particular r and d process, adverse litigation or government action, changes to laws and regulations applicable in order to our industry and the impact associated with public wellness outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that could affect AbbVie’s operations is set forth in Item 1A, “Risk Factors, ” of AbbVie’s 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking claims as a result of subsequent events or even developments, except as required by law.


Leave a Reply

Your email address will not be published. Required fields are marked *